Senti Biosciences Inc. (SNTI)
| Bid | 3.32 |
| Market Cap | 86.66M |
| Revenue (ttm) | 5.86M |
| Net Income (ttm) | -52.79M |
| EPS (ttm) | -12.03 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | -0.58 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 41,172 |
| Avg. Volume (20D) | 95,351 |
| Open | 3.27 |
| Previous Close | 3.25 |
| Day's Range | 3.15 - 3.36 |
| 52-Week Range | 1.52 - 16.94 |
| Beta | 2.33 |
About SNTI
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor onc...
Analyst Forecast
According to 1 analyst ratings, the average rating for SNTI stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 259.82% from the latest price.
Stock Forecasts
2 months ago · accessnewswire.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc.NEW YORK, NY / ACCESS Newswire / February 5, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company"...
2 months ago · accessnewswire.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences IncNEW YORK, NY / ACCESS Newswire / February 3, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company"...